By analyzing the expression profiles and GO functional enrichment, we unraveled that carriers of BRCA1/2 alterations and patients with miRNA deregulation shared a common mechanism that affected the prognosis of ovarian cancer treated with platinum-based chemotherapy. The gene discussed is BRCA1; the disease is ovarian cancer.